Report 49: Clotting System-Related Adverse Events Following Pfizer COVID-19 mRNA Vaccination
The War Room/DailyClout Pfizer Documents Analysis Project Post-Marketing Team created the following Thromboembolic System Organ Class (SOC) Review from data in Pfizer document 5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-FEB-2021 (a.k.a., “5.3.6“). The thromboembolic system is the human body’s clotting system and includes general activation of the clotting system, diffuse intravascular coagulation, which results in multi-organ damage throughout the body. It does not include clots that cause strokes or most other blood disorders. Thromboembolic Adverse Events (AEs) reports made up 0.3% of the total Adverse Events, including 18 deaths, with the vast majority reported from Europe and North America.
It is important to note that the Adverse Events in the 5.3.6 document were reported to Pfizer for only a 90-day period starting on December 1, 2020, the date of the United Kingdom’s public rollout of Pfizer’s COVID-19 experimental mRNA “vaccine” product.
Please read the full report below.DC V3 authors Post Marketing Team Thromboembolic micro report 5.3